{"id":"https://openalex.org/W3167458317","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.7539","title":"Lenalidomide plus rituximab in patients with rituximab-resistant indolent B-cell and mantle cell lymphomas: 10-year follow-up.","display_name":"Lenalidomide plus rituximab in patients with rituximab-resistant indolent B-cell and mantle cell lymphomas: 10-year follow-up.","publication_year":2021,"publication_date":"2021-05-20","ids":{"openalex":"https://openalex.org/W3167458317","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.7539","mag":"3167458317"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2021.39.15_suppl.7539","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.7539","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.7539","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049059991","display_name":"Aditi Gupta","orcid":"https://orcid.org/0000-0002-6286-802X","observed_orcids":["https://orcid.org/0000-0002-6286-802X"]},"institutions":[{"id":"https://openalex.org/I4210143392","display_name":"University of Pennsylvania Health System","ror":"https://ror.org/04h81rw26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditi Gupta","raw_affiliation_strings":["University of Pennsylvania Health System, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pennsylvania Health System, Philadelphia, PA;","institution_ids":["https://openalex.org/I4210143392"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080630441","display_name":"Stephen J. Schuster","orcid":"https://orcid.org/0000-0002-3376-8978","observed_orcids":["https://orcid.org/0000-0002-3376-8978"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen J. Schuster","raw_affiliation_strings":["Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005058090","display_name":"Jakub Svoboda","orcid":"https://orcid.org/0000-0002-6359-7065","observed_orcids":["https://orcid.org/0000-0002-6359-7065"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jakub Svoboda","raw_affiliation_strings":["University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088286702","display_name":"Sunita Dwivedy Nasta","orcid":"https://orcid.org/0000-0002-8981-2931","observed_orcids":["https://orcid.org/0000-0002-8981-2931"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunita Nasta","raw_affiliation_strings":["Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062705741","display_name":"Ellen B. Napier","orcid":"https://orcid.org/0000-0003-4019-6266","observed_orcids":["https://orcid.org/0000-0003-4019-6266"]},"institutions":[{"id":"https://openalex.org/I4210143392","display_name":"University of Pennsylvania Health System","ror":"https://ror.org/04h81rw26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ellen Napier","raw_affiliation_strings":["University of Pennsylvania Health System, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pennsylvania Health System, Philadelphia, PA;","institution_ids":["https://openalex.org/I4210143392"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040808358","display_name":"Kristy M. Walsh","orcid":"https://orcid.org/0000-0003-0229-5431","observed_orcids":["https://orcid.org/0000-0003-0229-5431"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristy Walsh","raw_affiliation_strings":["University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015896987","display_name":"Elise A. Chong","orcid":"https://orcid.org/0000-0001-8895-1625","observed_orcids":["https://orcid.org/0000-0001-8895-1625"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elise A. Chong","raw_affiliation_strings":["Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"15_suppl","first_page":"7539","last_page":"7539"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9829999804496765},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/rituximab-refractory-lymphoma","display_name":"rituximab-refractory lymphoma","score":0.8920000195503235},{"id":"https://openalex.org/keywords/indolent-b-cell-non-hodgkin-lymphoma","display_name":"indolent B-cell non-Hodgkin lymphoma","score":0.9810000061988831},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/marginal-zone-lymphoma","display_name":"marginal zone lymphoma","score":0.8659999966621399},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.7770000100135803},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9729999899864197},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9909999966621399},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.777999997138977},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.30300000309944153},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.5450000166893005}],"concepts":[{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.9300825595855713},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9233196973800659},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.6847130060195923},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.6805457472801208},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6555405855178833},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.650334358215332},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4881480634212494},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4230564534664154},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3875393569469452},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35901427268981934},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32821035385131836},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.20139232277870178},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2021.39.15_suppl.7539","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.7539","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.7539","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7599999904632568}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3031387218","https://openalex.org/W2028031208","https://openalex.org/W2519639378","https://openalex.org/W1682518818","https://openalex.org/W2183197933","https://openalex.org/W3032601586","https://openalex.org/W2406806223","https://openalex.org/W2416536760","https://openalex.org/W2350203434","https://openalex.org/W3029425576"],"abstract_inverted_index":{"7539":[0],"Background:":[1],"Lenalidomide":[2],"(len)":[3],"plus":[4,29,497,512],"rituximab":[5,30,72,88,108,498,511],"is":[6,214],"now":[7,47],"a":[8,90,145,361,426,439,506],"standard-of-care":[9],"option":[10],"for":[11,99,157,429,495],"indolent":[12],"B-cell":[13],"non-Hodgkin":[14],"lymphomas":[15,20],"(iNHL)":[16],"and":[17,37,71,111,162,174,184,191,200,216,225,231,233,238,243,249,251,256,282,321,347,386,424,458,482,505],"mantle":[18],"cell":[19,464],"(MCL).":[21],"We":[22,46,58,501],"previously":[23],"demonstrated":[24],"the":[25,49,208,473,491],"efficacy":[26],"of":[27,81,87,107,147,275,363,422,441,472],"len":[28,95,113,278,300,369,397,419,496],"in":[31,65,270,284,292,499],"patients":[32,474],"(pts)":[33],"with":[34,54,67,222,288,329,418,475,510],"rituximab-refractory":[35],"iNHL":[36,68],"MCL":[38,70],"(Chong":[39],"et":[40],"al.":[41],"Clin":[42],"Can":[43],"Res":[44],"2015).":[45],"report":[48],"longest":[50,492],"experience":[51],"to":[52,77,358,372,405,469],"date":[53],"this":[55],"regimen.":[56,92],"Methods:":[57],"conducted":[59],"an":[60],"open-label":[61],"phase":[62],"II":[63],"trial":[64,516],"pts":[66,124,159,210,221,262,434],"or":[69,79,89,119],"resistance,":[73],"defined":[74],"as":[75],"failure":[76],"respond":[78],"progression":[80],"disease":[82,116],"within":[83],"6":[84],"months":[85],"(mo)":[86],"rituximab-containing":[91],"Pts":[93,143,354],"received":[94,144,479,485],"10":[96,163],"mg":[97,303],"daily":[98],"8":[100],"weeks,":[101],"followed":[102],"by":[103],"4":[104,131,261],"weekly":[105],"doses":[106],"375":[109],"mg/m2":[110],"continued":[112],"maintenance":[114],"until":[115],"progression,":[117],"toxicity":[118,359],"pt":[120,287,409],"choice.":[121],"Results:":[122],"50":[123],"(30":[125],"FL,":[126,223,264],"14":[127],"MCL,":[128,241,266],"2":[129,380,413,450],"MZL,":[130],"SLL)":[132],"were":[133,211,228,236,246,254,316,341],"treated":[134],"between":[135],"2008-2012.":[136],"Median":[137],"follow-up":[138],"was":[139,165,179,196,416],"10.5":[140,259],"years":[141],"(yr).":[142],"median":[146,362,440],"3":[148,274,459],"prior":[149],"therapies":[150],"(range:":[151,444],"1\u20137).":[152],"Progression":[153],"free":[154],"survival":[155,194],"(PFS)":[156],"all":[158,327],"at":[160,279,301,360,438],"5":[161,302,430,432],"yrs":[164],"20.0%":[166],"[95%CI":[167,171,198,202],"8-35]":[168],"&":[169],"13%":[170],"3-30%];":[172],"5-":[173,190,224,232,242,250],"10-yr":[175,192,217,226,234,244,252],"response":[176],"duration":[177],"(RD)":[178],"27%":[180],"[95%":[181,186],"CI":[182,187],"12-46]":[183],"18%":[185],"4-40],":[188],"respectively;":[189],"overall":[193],"(OS)":[195],"58%":[197],"43-70]":[199],"45%":[201],"30-58],":[203],"respectively.":[204],"5-yr":[205],"OS":[206,218,235,253],"from":[207,368,446],"time":[209],"deemed":[212],"rituximab-resistant":[213],"64.0%":[215],"51.9%.":[219],"For":[220,240],"PFS":[227,245],"both":[229,247],"13%,":[230],"60%":[237],"40%.":[239],"25%":[248],"50%":[255],"36%.":[257],"At":[258],"yr,":[260],"(2":[263],"1":[265,267,286,394,400],"MZL)":[268],"remain":[269],"complete":[271],"remission":[272],"(CR),":[273],"whom":[276],"discontinued":[277,290,355,396],"7.0-yr,":[280],"8.8-yr":[281],"10.1-yr":[283],"CR.":[285],"FL":[289],"study":[291],"CR":[293,428],"after":[294,398],"11.6-yr":[295],"but":[296],"continues":[297],"on":[298],"commercial":[299],"daily.":[304],"The":[305,332,408],"most":[306,333],"common":[307,334],"grade":[308,335,373,379,387,412],"1\u20132":[309],"adverse":[310],"events":[311],"(AEs)":[312],"requiring":[313,338],"dose":[314,330,339],"reductions":[315,340],"neuropathy":[317],"(n":[318,323,343,350,376,383,390],"=":[319,324,344,351,377,384,391],"3)":[320],"diarrhea":[322],"5),":[325],"which":[326],"resolved":[328],"reduction.":[331],"3\u20134":[336,374,388],"AEs":[337],"neutropenia":[342],"6,":[345],"12%)":[346],"tumor":[348],"flare":[349],"3,":[352],"6%).":[353],"therapy":[356],"due":[357,371,404],"4.9":[364],"mo":[365,443],"(range":[366],"0.3\u201325.7)":[367],"start":[370],"rash":[375],"2),":[378],"abdominal":[381,414],"pain":[382,415,423],"1),":[385],"thrombocytopenia":[389],"2).":[392],"Only":[393],"patient":[395],">":[399],"yr":[401],"(25.7":[402],"mo)":[403],"persistent":[406],"diarrhea.":[407],"who":[410],"developed":[411,435],"retreated":[417],"without":[420],"recurrence":[421],"sustained":[425],"second":[427],"yrs.":[431],"(10%)":[433],"secondary":[436,476],"cancers":[437,461,477],"15.5":[442],"0.8\u201350.5)":[445],"starting":[447],"len,":[448],"including":[449],"hematological":[451],"(acute":[452],"myeloid":[453],"leukemia,":[454],"B-acute":[455],"lymphoblastic":[456],"leukemia)":[457],"solid":[460],"(NSCLC,":[462],"renal":[463],"carcinoma,":[465],"prostate":[466],"cancer).":[467],"Prior":[468],"enrollment,":[470],"4/5":[471],"had":[478,484],"alkylating":[480],"agents":[481],"3/5":[483],"anthracyclines.":[486],"Conclusions:":[487],"These":[488],"data":[489],"represent":[490],"reported":[493],"outcomes":[494],"NHLs.":[500],"demonstrate":[502],"durable":[503],"responses":[504],"manageable":[507],"safety":[508],"profile":[509],"low-dose":[513],"len.":[514],"Clinical":[515],"information:":[517],"NCT00783367.":[518]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2025-10-10T00:00:00"}